The Nasdaq-listed biotech sold 9,387,896 ordinary shares and pre-funded warrants for 525,897 shares, with the underwriters’ full take-up lifting gross proceeds above the initially announced $125 million.
Crescent Biopharma closed its previously announced underwritten public offering, raising about $143.7 million in gross proceeds before fees and expenses after underwriters fully exercised their option to buy additional shares. The deal included 9,387,896 ordinary shares, which reflects the sale of 1,293,103 additional shares under the option, and pre-funded warrants to purchase up to 525,897 ordinary shares for certain investors. The ordinary shares were sold at $14.50 each, while the pre-funded warrants were priced at $14.499 each, representing the public share price less the $0.001 per-share exercise price. Jefferies, TD Cowen, Guggenheim Securities and Cantor acted as joint book-running managers, and LifeSci Capital acted as passive book-running manager. The securities were offered under an SEC shelf registration statement on Form S-3 that became effective on July 10, 2026, and Crescent said a final prospectus supplement and accompanying prospectus have been filed with the SEC. Crescent, a clinical-stage oncology company, said its pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates for solid tumors.